<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03276455</url>
  </required_header>
  <id_info>
    <org_study_id>NanFangHospital</org_study_id>
    <nct_id>NCT03276455</nct_id>
  </id_info>
  <brief_title>Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified</brief_title>
  <official_title>Evaluation of Safety and Efficacy of Transplantation of Autologous Hematopoietic Stem Cell Genetically Modified in Beta-Thalassemia Major</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Yike Gene Science and Technology CO.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single group, open label study in 10 subjects who are 8 years of age or older with&#xD;
      beta-thalassemia major. The objective of this study is to evaluate the safety and efficacy of&#xD;
      autologous hematopoietic stem cell transduced with lentiviral vector for the treatment of&#xD;
      beta-thalassemia major.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Beta-thalassemia major is a life-threatening genetic disease of red cell malfunction. It is&#xD;
      caused by mutations in the beta-globin gene which encodes the beta-globin protein, leading to&#xD;
      the ineffective erythropoiesis, hemolysis and anemia. Transplantation of allogeneic&#xD;
      hematopoietic stem cells (HSCT) is the only available cure which is, however, has the&#xD;
      significant risk of transplant related mortality, graft versus host disease and limited&#xD;
      source. Therefore, transplantation of autologous hematopoietic stem cells will be an&#xD;
      attractive therapeutic treatment for beta-thalassemia major patients. 10 patients will be&#xD;
      treated with genetically modified autologous hematopoietic stem cells which transduced with&#xD;
      lentiviral vector encoding for beta-globin gene.&#xD;
&#xD;
      Patients will participate for this study for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 15, 2017</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of adverse events</measure>
    <time_frame>0-36 months after transplantation</time_frame>
    <description>Evaluate the safety of treatment with transplantation of autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene as measured by the incidence of adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hemoglobin conten</measure>
    <time_frame>3-36 months after transplantation</time_frame>
    <description>Evaluate the efficacy of treatment with transplantation of autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene by the detection hemoglobin content of peripheral blood cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic stem cell engraftment</measure>
    <time_frame>42 days after transplantation</time_frame>
    <description>Success and kinetics of hematopoietic stem cell engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RCL</measure>
    <time_frame>1-36 months after transplantation</time_frame>
    <description>The generation of a replication-competent lentivirus (RCL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VCN</measure>
    <time_frame>1-36 months after transplantation</time_frame>
    <description>Quantify gene transfer efficiency and expression by evaluation of average vector copy number(VCN) in blood or bone marrow cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bete-globin content</measure>
    <time_frame>1-36 months after transplantation</time_frame>
    <description>Evaluate the efficacy of treatment by detection of bete-globin content of HGB of peripheral blood cells.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Beta Thalassemia Major</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beta-thalassemia major subjects who are 8 years age or older are transplated by autologous CD34+ cells genetically modified(autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene).</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Autologous CD34+ cells genetically modified</intervention_name>
    <description>Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be 8 years of age or older.&#xD;
&#xD;
          -  Subjects or their parents/legal guardians must be able to understand and voluntarily&#xD;
             sign an informed consent form.&#xD;
&#xD;
          -  Subjects must have a confirmed diagnosis of ß-thalassemia major and&#xD;
&#xD;
             ≥100 mL/kg/year of pRBCs or ≥ 8 transfusions of pRBCs per year over a minimum of two&#xD;
             years prior to entry onto the study.&#xD;
&#xD;
          -  Subjects must be in clinically stable condition and eligible for hematopoietic stem&#xD;
             cell transplantation.&#xD;
&#xD;
          -  Subjects must satisfy Karnofsky index ≥80% for adults or Lansky index&#xD;
&#xD;
             ≥70% for children.&#xD;
&#xD;
          -  Subjects must have survival expectancy of greater than 6 months.&#xD;
&#xD;
          -  Subjects must have been treated and followed up for at least the past 2 years in&#xD;
             specialized institutions where they have comprehensive assessment of the&#xD;
             disease（including psychiatric assessment），and detailed medical materials at least the&#xD;
             past 2years so as to self-contrast before and after treatment.&#xD;
&#xD;
          -  Subjects must discontinue treatment of hydroxyurea, 5-azoside or cytarabine at least&#xD;
             three months prior to entry onto the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having an HLA-matched donor(sibling or of a suitable 10/10 matched unrelated donor).&#xD;
&#xD;
          -  Positivity for HIV (serology or RNA), and/or HbsAg and/or HBV DNA and/or HCV RNA (or&#xD;
             negative HCV RNA but on antiviral treatment).&#xD;
&#xD;
          -  Contraindication to anesthesia for bone marrow collection.&#xD;
&#xD;
          -  Severe, bacterial, active viral, or fungal infection, etc.&#xD;
&#xD;
          -  The history of malignant tumor.&#xD;
&#xD;
          -  The white blood cell (WBC) count &lt;3000/uL and/or platelet count &lt;100,000/uL exclude&#xD;
             hypersplenism factor.&#xD;
&#xD;
          -  Family history of familial cancer syndromes (including but not limited to Hereditary&#xD;
             breast and ovarian syndrome, hereditary non-polyp colorectal cancer syndrome, familial&#xD;
             adenomatous polyposis).&#xD;
&#xD;
          -  Previous allogeneic bone marrow transplantation.&#xD;
&#xD;
          -  The history of psychosis and any psychiatric disorder.&#xD;
&#xD;
          -  Active substance abuse, drug or alcohol abuse recently.&#xD;
&#xD;
          -  The history of complex allo-immunization which could cause difficulty administering&#xD;
             transfusions.&#xD;
&#xD;
          -  Female adults who are pregnant , breast feeding or lack of effective contraception.&#xD;
&#xD;
          -  History of major organ damage including:&#xD;
&#xD;
        Severe cerebrovascular disease or cognitive sequelae, including hemiplegia. Severe liver&#xD;
        disease with alanine transaminase (ALT) &gt;3 upper limit of normal. Severe liver cirrhosis or&#xD;
        fibrosis on liver biopsy. Heart disease with ejection fraction&lt;25% or T2* &lt;10 ms by&#xD;
        magnetic resonance imaging (MRI). Kidney disease with creatinine clearance &lt;30% normal&#xD;
        value. Lung disease, including pulmonary fibrosis, pulmonary arterial hypertension or&#xD;
        pulmonary function tests below standard (i.e., pO2&lt;90 mmHg and/or carbon dioxide diffusion&#xD;
        coefficient&lt;50%). Endocrine disorder including insulin dependent diabetes mellitus,&#xD;
        Hyperthyroidism or deficiency, Hyperparathyroidism or deficiency.&#xD;
&#xD;
          -  Participation in another clinical study within 30 days of screening.&#xD;
&#xD;
          -  Subjects with severe iron overload determined by the researchers.&#xD;
&#xD;
          -  Any other situation that unsuitably undergoing hematopoietic stem cell transplantation&#xD;
             determined by the physicians or researchers.&#xD;
&#xD;
          -  Presence of chromosomal abnormalities by bone marrow detected.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunfu Li, PhD</last_name>
    <phone>86-020-61641921</phone>
    <email>chunfugzcn@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhiyong Peng</last_name>
    <phone>86-020-61641925</phone>
    <email>pengzhiyong8@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanfang Hospial</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>ChunFu Li, PhD</last_name>
      <phone>86-020-61641921</phone>
      <email>chunfugzcn@126.com</email>
    </contact>
    <investigator>
      <last_name>ChunFu Li, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 6, 2017</study_first_submitted>
  <study_first_submitted_qc>September 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Chunfu Li</investigator_full_name>
    <investigator_title>Director and professor</investigator_title>
  </responsible_party>
  <keyword>Beta thalassemia</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Beta-globin</keyword>
  <keyword>Hematopoietic stem cells</keyword>
  <keyword>Lentiviral vector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

